In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Adaptimmune nets $178mm in IPO

08 May 2015

Executive Summary

Less than a year after closing its $104mm Series A round (the largest Series A in 2014), UK-based Adaptimmune Therapeutics PLC (T-cell therapy) netted $178mm in its US initial public offering of 11.2mm ADSs (representing 67.5mm ordinary shares) for $17. The company planned to sell 9.4mm ADSs (representing 56.2mm ordinary shares) for $15-17.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By